AB0495 Post-marketing surveillance of tofacitinib in japanese patients with rheumatoid arthritis: an interim report of safety data

Naoto Tamura ,Masataka Kuwana ,Masayoshi Harigai ,Yutaka Endo ,Shuji Takei ,Shigeki Momohara ,Naonobu Sugiyama ,Kazuhiko Yamamoto ,Yosuke Morishima ,Tsuneyo Mimori ,Noritoshi Yoshii ,Tomoyuki Fujii ,Kazuto Nomura ,Tatsuya Atsumi ,Tomohiro Hirose ,Hiroaki Matsuno ,Michiaki Takagi

doi:10.1136/annrheumdis-2018-eular.3521

AB0495 Post-marketing surveillance of tofacitinib in japanese patients with rheumatoid arthritis: an interim report of safety data

Naoto Tamura , Masataka Kuwana + Show 15 more

Open Access

https://doi.org/10.1136/annrheumdis-2018-eular.3521

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2018

Affiliation: Juntendo University Hospital, Nippon Medical School, Tokyo Women's Medical University, Pfizer (Japan), Kagoshima University, Kishokai Medical Corporation, The University of Tokyo, Kyoto University, Wakayama Medical University, Hokkaido University, Sapporo University, Institute for Rheumatic Diseases (Japan), Yamagata University

#All Adverse Events #Japanese Pts + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib have been shown in patients (pts) with RA in global Phase...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.